Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$7.06M
Enterprise Value-$1.53M
Total Cash (Recent Filing)$7.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.22
Enterprise Value/Revenue-0.48
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure reduces refinancing and interest-rate risks, giving management flexibility to fund R&D or operations via equity or partnerships. This durable strength materially lowers bankruptcy risk and supports runway while the company pursues commercialization milestones.
Revenue Growth With High Gross MarginsSustained top-line growth paired with high gross margins indicates the business can scale revenue without proportionate COGS pressure. Over months this supports potential margin expansion once operating leverage improves, making future pathway to profitability more viable if operating costs are controlled.
Executive Retention Via Equity AwardA multi-year restricted stock award aligns interim CEO/CFO incentives with long-term value creation and continuity. This structural governance move can improve strategic execution and reduce turnover risk, supporting consistent R&D and partnership efforts across the next several years.
Bears Say
Deep And Persistent UnprofitabilityLarge negative net margins reflect chronic inability to convert revenues into profits, implying the company must either materially cut operating spend or deliver major revenue gains to reach break-even. Over a multi-month horizon this limits self-funding and raises execution risk for clinical programs.
Ongoing Negative Operating Cash FlowRepeated negative operating cash flow signals continued cash burn and reliance on external financing to fund operations and trials. Even if burn has eased from peaks, persistent outflows over months increase funding risk and can force dilution or strategic compromises if capital markets tighten.
Erosion Of Shareholder Equity And Negative ROESubstantial equity erosion and negative ROE reflect cumulative losses that diminish shareholder capital and limit balance-sheet resilience. Over the medium term this constrains strategic optionality, making the company more sensitive to cash shocks and less able to absorb setbacks in drug development.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $7.06M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 69 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.2.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.159%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.36% Insiders
0.87% Mutual Funds
0.12% Other Institutional Investors
94.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---